Related Experiment Video
Updated: Dec 29, 2025
07:41
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.4K
Identification of Platform-Independent Diagnostic Biomarker Panel for Hepatocellular Carcinoma Using Large-Scale
Harpreet Kaur1,2, Anjali Dhall2, Rajesh Kumar1,2
1Bioinformatics Center, CSIR-Institute of Microbial Technology, Chandigarh, India.
Frontiers in Genetics
|January 31, 2020
Summary
Researchers identified a universal, platform-independent three-gene biomarker panel (FCN3, CLEC1B, PRC1) for early hepatocellular carcinoma (HCC) diagnosis. This panel demonstrates high accuracy and prognostic potential, aiding in patient stratification and improving early detection strategies for HCC.
Area of Science:
- Oncology
- Genomics
- Biomarker Discovery
Background:
- Hepatocellular carcinoma (HCC) has a high mortality rate, largely due to late diagnosis.
- Previous attempts at genetic biomarker discovery for HCC were limited by small datasets and lack of cross-platform validation.
- A universal, platform-independent diagnostic biomarker is needed for early HCC detection.
Purpose of the Study:
- To identify a universal, platform-independent gene expression-based biomarker panel for HCC diagnosis.
- To evaluate the diagnostic accuracy and non-invasive utility of the identified biomarker panel.
- To assess the prognostic potential of the identified genes in HCC patient cohorts.
Main Methods:
- Utilized large-scale transcriptomic profiling datasets (2,316 HCC, 1,665 non-tumorous samples) from 30 studies across multiple platforms (Affymetrix, Illumina, Agilent, High-throughput sequencing).
- Scrutinized overlapping differentially expressed genes and employed feature selection techniques to identify a three-gene panel (FCN3, CLEC1B, PRC1).
- Validated diagnostic performance using training/validation datasets and peripheral blood mononuclear cells; assessed prognostic potential via univariate survival analysis on TCGA-LIHC and GSE14520 cohorts.
Main Results:
- A three-gene panel (FCN3, CLEC1B, PRC1) was identified as a robust HCC biomarker.
- The panel achieved high diagnostic accuracy (93-98%) and Area Under ROC Curve (AUROC 0.97-1.0) in training/validation datasets.
- Demonstrated non-invasive utility with AUROC of 0.91-0.96 in peripheral blood mononuclear cells and significant prognostic value, stratifying patients by survival risk (p<0.05).
Conclusions:
- A universal, platform-independent three-gene biomarker panel (FCN3, CLEC1B, PRC1) for HCC diagnosis with high precision was identified.
- The biomarker panel exhibits significant prognostic potential, aiding in the stratification of HCC patients based on survival risk.
- A web server, HCCpred, was developed to facilitate the use of this biomarker panel by the scientific community.
